

16th December, 2019

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release – Cipla Limited acquires trademark rights of Vysov

Dear Sir/Madam,

Please find enclosed press release dated 16th December, 2019 for the captioned subject.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary

Encl: as above

Prepared by: Juzer Masta



Cipla acquires trademark rights of Vysov

Mumbai, 16th December 2019: Cipla Ltd. (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") has acquired the brand name and trademark rights for Vysov® & Vysov M® (Vildagliptin + Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market.

The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov® & Vysov M® and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country.

Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves glycemic control in patients primarily by enhancing pancreatic (α and β) islet functions. The drug is backed by strong clinical data & is therefore a widely prescribed antidiabetic medicine for adults with type 2 diabetes mellitus. The current market size of Vildagliptin is INR 818 Cr. as per IQVIA MAT Nov' 2019 in India.

Mr. Nikhil Chopra, Executive Vice-President & Head India Business, Cipla Ltd. said "Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov® will enable us to contribute to easier access of the drug in India."



ABOUT CIPLA

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sept'19), 3rd largest in the pharma private market in South Africa (IQVIA MAT Sept'19), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.ciplalimited.com or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com